ArticleEye (London, England)2024

Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema.

Grace A Borchert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.